This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Halo Collective Valuation

Is HALO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HALO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HALO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HALO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HALO?

Key metric: As HALO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HALO. This is calculated by dividing HALO's market cap by their current revenue.
What is HALO's PS Ratio?
PS Ratio	0.1x
Sales	US$18.30m
Market Cap	US$2.71m

HALO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.8x
Enterprise Value/EBITDA	-0.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does HALO's PS Ratio compare to its peers?

The above table shows the PS ratio for HALO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.4x
RAMM RAMM Pharma	0.4x	n/a	CA$1.2m
LOWL Lowell Farms	0.01x	n/a	CA$363.0k
AREV AREV Life Sciences Global	15.5x	n/a	CA$2.9m
THC THC Biomed Intl	1.5x	n/a	CA$3.3m
HALO Halo Collective	0.1x	n/a	CA$2.7m

Price-To-Sales vs Peers: HALO is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (7.9x).

Price to Sales Ratio vs Industry

How does HALO's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

26 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	0.8x	10.8%
HALO Halo Collective	0.1x	n/a	US$2.71m
AYR.A Ayr Wellness	0.2x	2.6%	US$78.97m
TIUM.U Cansortium	0.2x	n/a	US$22.65m

26 Companies		Estimated Growth	Market Cap
Industry Avg.	0.8x	53.5%
HALO Halo Collective	0.1x	n/a	US$2.71m

No more companies

Price-To-Sales vs Industry: HALO is good value based on its Price-To-Sales Ratio (0.1x) compared to the Canadian Pharmaceuticals industry average (0.9x).

Price to Sales Ratio vs Fair Ratio

What is HALO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HALO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate HALO's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Verano Holdings

CA$765.1m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.02

-14.8%

-65.2%

Fennec Pharmaceuticals

US$129.5m

Operates as a biopharmaceutical company in the United States.

FRX

US$7.35

30.1%

-38.9%

Cresco Labs

CA$709.6m

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.

CA$1.51

-23.4%

-32.3%